Compounded mAbs - Cancer Therapies
Estimated value
£216.0m
Awarded value
—
Suppliers
0
Lots
2
Published
07 May 2026
Description
Phamacy Procurement Contract - A ranked framework for the supply and delivery of Compounded Monoclonal Antibodies (mAbs) for Intravenous Infusion for Chemotherapy indications split into 2 lots: Lot 1: High Volume Products - 5 molecules / all brands Lot 2: Lower Volume Products - 13 molecules / all brands The ranked framework will be open to the participating Trusts of the South East Pharmacy Procurement Service (SEPPS): Thames Valley and Wessex (TV&W) 1. Buckinghamshire Healthcare NHS Trust 2. Frimley Health NHS Foundation Trust 3. Hampshire Hospitals NHS Foundation Trust 4. Isle of Wight NHS Trust 5. Hampshire and Isle of Wight Healthcare NHS Foundation Trust 6. Milton Keynes University Hospital NHS Foundation Trust 7. Oxford Health NHS Foundation Trust 8. Oxford University Hospitals NHS Foundation Trust 9. Portsmouth Hospitals NHS Trust 10. Royal Berkshire NHS Foundation Trust 11. University Hospital Southampton NHS Foundation Trust South-East Coast (SEC) 12. Ashford and St. Peters’ Hospitals NHS Foundation Trust 13. Dartford and Gravesham NHS Trust 14. East Kent Hospitals University NHS Foundation Trust 15. East Sussex Healthcare NHS Trust 16. Kent Community Health NHS Trust 17. Maidstone & Tunbridge Wells NHS Trust 18. Medway NHS Foundation Trust 19. Queen Victoria Hospitals NHS Foundation Trust 20. Royal Surrey County Hospital NHS Foundation Trust 21. Surrey and Borders Partnership NHS Foundation Trust 22. Surrey and Sussex Healthcare NHS Trust 23. Sussex Community NHS Trust 24. Sussex Partnership NHS Foundation Trust 25. University Hospitals Sussex NHS Foundation Trust 26. Berkshire Healthcare NHS Foundation Trust This framework will be available for use by Trusts in East of England and London regions, but the volumes for these regions have not been included for adjudication as part of the tender process. SEC Trusts can utilise this tender for products or services not covered by the National unlicensed aseptically prepared cytotoxic medicines and mAbs framework via MPSC. Please note: we did not publish a preliminary market engagement notice (UK2) for the following reasons: - we are not seeking to further develop our requirements or procurement approach. - we have procured similar supply arrangements via the Open procedure and deployed similar conditions of participation and award criteria. These have yielded good results previously. - we have already prepared our tender pack (see attached), that detail standard NHS contractual terms which have been found to be acceptable to the supply chain. - we understand the likely suppliers who will be interested but the open notice approach gives opportunity to others looking to enter the mAbs supply market
Scope
- Reference
- PR BHFT 0715
- Total value
- £216,000,000 excluding VAT£259,200,000 including VATAbove the relevant threshold
- Commercial tool
- Standalone contract
- Contract dates
- 01 Dec 2026 to 30 Nov 2028Possible extension to 30 Nov 2030
Option for 2 x 12 month extension (maximum duration 4 years).
- Main category
- services
- CPV classifications
- 3360000085149000
- Contract locations
- UK, United KingdomSouth East England, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Procurement Specific Questionnaire | Pass/Fail - see Tender Pack - ITT Instructions for detail | quality | 0.01% |
| Framework Agreement T&Cs Acceptance | Pass/Fail - see Tender Pack - ITT Instructions for detail | quality | 0.01% |
| Technical Compliance/ Technical Capability/ Quality Assurance (40%) | Technical Compliance / Technical Capability/ Quality Assurance. Responses to Technical Questions - see Tender Pack - ITT Instructions for detail. Note: MHRA Licensing is Pass/Fail | quality | 39.98% |
| Social Value (10%) | Responses to Social Value Questions - see Tender Pack - ITT Instructions for detail. | quality | 10.00% |
| Shelf Life (15%) | Shelf Life Assessment - see Tender Pack - ITT Instructions for detail | quality | 15.00% |
| Price (35%) | Assessment of Pricing Model - see Tender Pack - ITT Instructions for detail | price | 35.00% |
Participation
Conditions suppliers must meet to bid.
See Tender Pack
Submission & procedure
- Enquiry deadline
- 02 Jun 2026, 11:00 am
- Submission deadline
- 08 Jun 2026, 11:15 am
- Submission address
- https://health-family.force.com/s/Welcome ↗
- Electronic submission
- Yes
- Procedure
- Open procedure
Lots · 2 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 | £170.6m | active |
| 2 | Lot 2 | £45.4m | active |